Bausch Health Companies Inc. (BHC) News
Filter BHC News Items
BHC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BHC News Highlights
- BHC's 30 day story count now stands at 28.
- Over the past 24 days, the trend for BHC's stories per day has been choppy and unclear. It has oscillated between 1 and 7.
- SKIN, AMD and EYE are the most mentioned tickers in articles about BHC.
Latest BHC News From Around the Web
Below are the latest news stories about Bausch Health Companies Inc that investors may wish to consider to help them evaluate BHC as an investment opportunity.
Bausch's (BHC) Q4 Earnings Beat Estimates, Revenues MissBausch (BHC) beats on earnings but misses on sales in the fourth quarter. The outlook for 2022 is disappointing. |
Bausch Health Announces Participation At The J.P. Morgan Global High Yield & Leveraged Finance ConferenceBausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that Sam Eldessouky, executive vice president and chief financial officer; William Woodfield, senior vice president and treasurer; and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the J.P. Morgan Global High Yield & Leveraged Finance Conference in Miami on March 1, 2022 at 9:15 a.m. ET. |
Bausch Health Companies Inc. (BHC) CEO Joseph Papa on Q4 2021 Results - Earnings Call TranscriptBausch Health Companies Inc. (BHC) Q4 2021 Results Conference Call February 23, 2022 08:00 AM ET Company Participants Arthur Shannon - SVP, Head of IR Joseph Papa - Chairman, CEO Sam Eldessouky - CFO Thomas Appio - President, Co-Head Bausch + Lomb/International Scott Hirsch - CEO, Solta Medical Conference Call... |
Bausch Health Swings to Profit in Q4Bausch Health Companies (TSE: BHC) (NYSE: BHC) swung to a profit from a loss in the fourth quarter of 2021. The manufacturer of health care products is fully ready to launch Solta and Bausch + Lomb IPOs. Revenues & Earnings Revenues came in at $2.196 billion for the quarter ended December 31, up 1% from $2.213 billion in the prior-year quarter. The company reported a GAAP net income of $69 million ($0.19 per share) in Q4 2021, compared to a net loss of $153 million (-$0.43 per share) in Q4 2020. |
Bausch Health (BHC) Beats Q4 Earnings EstimatesBausch (BHC) delivered earnings and revenue surprises of 17.59% and 0.45%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Bausch Health swings to a profit, while revenue and full-year outlook misses expectationsShares of Bausch Health Companies Inc. rallied 2.3% in premarket trading Wednesday, after the health care products company swung to fourth-quarter net income, while revenue and the full-year outlook fell shy of expectations. The company swung to net income of $69 million, or 19 cents a share, from a loss of $153 million, or 43 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted net income slipped to $463 million from $478 million, but the company did not provide adjuste |
Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2021 Results And Provides 2022 GuidanceFourth-Quarter 2021 Financial Results |
Bausch Health Can't Seem to Pass Its Chart Exam as Earnings ApproachBHC is due to report their latest earning's figures on Wednesday before the market opens. In this updated daily bar chart of BHC, below, we can see that prices have been on defense the past 12 months. BHC is trading below the declining 50-day moving average line as well as the declining 200-day line. |
Drug/Biotech Stocks' Q4 Earnings on Feb 23: BMRN, BHC & MoreLet us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23. |
OraPharma Launches OraFit™ Custom Clear Dental Aligner SystemBausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its oral health care business, OraPharma, today announced the U.S. launch of the OraFit™ custom clear aligner system, which is indicated for correcting malocclusion, which is also known as crooked or misaligned permanent teeth. The new OraFit™ aligner system uses high-performance materials in a three-layer design that offers dental professionals and their patients the latest in clear aligner technology and addresses the increased |